Tempus AI Launches Immune Profile Score to Enhance Cancer Treatment
Slice of Healthcare Team
Nov 12, 2024
Key Highlights
- Tempus AI launches Immune Profile Score (IPS) for clinicians to advance cancer care.
- Prognostic tool for stage IV pan-solid tumors undergoing immune checkpoint inhibitor (ICI) therapies.
- Validated in a study with 1,600 patients, IPS indicates survival benefits for "IPS-High" patients.
- Independent of traditional biomarkers like TMB, PD-L1, and MSI.
- Now available as an add-on to Tempus’ xT (DNA) and xR (RNA) assays.
Source: Business Wire
Notable Quotes
“ This study demonstrates that IPS scoring is beneficial in that it can identify patients, independent of standard biomarkers, who may have better overall survival with ICI therapy. ”
Sandip Patel, MD, Professor at UC San Diego Health
“ We are excited to introduce this innovative test to clinicians, empowering them with the ability to make more informed choices for their patients. ”
Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus
